This article highlights the commercial challenges facing gene therapies and flicks at a couple of important points that are worth further exploration.
read full article ›For those interested in how biotech and pharma companies communicate about drug value, patient access, and pricing philosophies, corporate responsibility reports are required reading. Many times these reports appear transparent, but aren't given information is averaged across the entire portfolio.
read full article ›Today’s WSJ article on copay alternate funding models (AFM) is the latest in a series of stories in the mainstream media about a game of chicken between drugmakers and payers. It's sure to be a hot topic at #Asembia23, the annual confab happening now in Las Vegas focused on all things specialty drug related.
read full article ›Pharma peeps: is medication co-pay affordability specifically for your Medicare patients a top concern? @Real Endpoints has developed an AI-based tool that might be of interest. Watch the video for more information and reach out to Susan Raiola, Julia Murphy, or Denise Wolff, Pharm D for more.
read full article ›With the news that Giovanni Caforio is handing the baton to Chris Boerner, I think we can say we called this one right. In all seriousness, it's no surprise to us that companies recognize the importance of putting people with deep market access roots into leadership positions. The commercial landscape is only growing more complex.
read full article ›Real Endpoints, the leading market-access platform and advisory firm, announces that four biopharma companies with combined 2022 sales of nearly $8 billion have signed contracts to offer Real Endpoint's RE Assist tool to support Medicare patients in need of deductible and copay assistance. RE Assist provides actionable, comprehensive foundation fund information in a compliant and easy to navigate format.
read full article ›The use of warranties – and more broadly, outcomes-based contracting - is a topic that’s sure to come up in an invitation-only meeting I am co-hosting with Roger Longman and Jeff Berkowitz from Real Endpoints, as well as LEK’s Pierre Jacquet and Orsini’s Nick Calla.
read full article ›Thanks to AMCP for hosting a session on value based contracting in healthcare at this year's annual meeting in San Antonio. The packed house underscored how important it is to find alignment between payers and manufacturers to increase market access for transformative therapies. Thanks to Michael A. Ford, R.Ph. and moderator Dean Hakanson MD for joining Real Endpoints' Jane F. Barlow, MD, MPH, MBA in sharing their views.
read full article ›Having just returned from the Informa Access USA conference, we can confirm that the so-called “specialty carve out” or “alternative funding” tactics being used by third-party brokers remain a hot topic of discussion.
read full article ›